MISSISSAUGA, ON, June 20, 2017 /CNW/ - Crescita Therapeutics Inc. (TSX:CTX) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms, today announced that at its 2017 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 17, 2017 were elected as directors of the Company.
The detailed results of the votes by proxy are as follows:
| Director Nominees |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
| FOR |
WITHHELD |
FOR |
WITHHELD |
|
| Daniel N. Chicoine |
5,308,089 |
237,704 |
95.71 |
4.29 |
| David A. Copeland |
5,332,506 |
213,287 |
96.15 |
3.85 |
| Anthony E. Dobranowski |
5,343,730 |
202,063 |
96.36 |
3.64 |
| John C. London |
5,308,318 |
237,475 |
95.72 |
4.28 |
| Samira Sakhia |
5,367,927 |
177,866 |
96.79 |
3.21 |
| Thomas Schlader |
5,357,071 |
188,722 |
96.60 |
3.40 |
About Crescita Therapeutics Inc.
Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. For additional information, please visit www.crescitatherapeutics.com.
SOURCE Crescita Therapeutics Inc.
PLEASE CONTACT: Investor Relations, Email: [email protected]
Share this article